CSE PREV
LAST 0.025
CHANGE 0.005
OTC PRVCF
FSE 18H
CSE: PREV
LAST: 0.025
CHANGE: 0.005
OTC: PRVCF
FSE: 18H

BSV Peptide Program

Targeting Cancer Progression

PreveCeutical, and research partner Uniquest, are currently screening peptides isolated from Caribbean Blue Scorpion venom across some of the most aggressive diseases where there exists unmet clinical need, such as cancer. There are numerous research papers in the public domain which show the anecdotal findings and efficacy of venom peptides taken through the proven route of administration on cancerous cells/tumours.

Recently the Company announced positive results from the preliminary screening of key peptides from its scorpion venom-derived peptide research and development program that is expected to enable PreveCeutical to generate Nature Identical™ peptide therapeutics intended for therapeutic applications.  PreveCeutical’s initial focus is to understand the activities of such peptides in cell-based brain cancer models.

Through preliminary screening in a glioblastoma cell-based assay, PreveCeutical’s research team has successfully identified four lead peptides that inhibit the activity of a target protein implicit in the progression of certain aggressive brain cancers. 

Further, the re-designed and synthesized peptides were found to be equally or more potent in the cell-based activity assay when compared to another scorpion peptide, Chlorotoxin.  A series of more comprehensive screening assays are underway in the final stage of the Peptide Program, to allow the Company to develop a more detailed understanding of the activities of the peptides in progressively complex cell-based brain cancer models.

Sign up for the latest news and updates